Shivalik Rasayan Jumps 20% — What’s Behind the Rally?

Spread love

By S. JHA

The agrochemicals and API maker’s shares have now risen in back-to-back weekly legs of 16% and 18%, culminating in Wednesday’s 20% surge. There’s no single disclosed trigger for the latest move — but there is a recent capital raise, and a former director’s share sales.

Mumbai, September 10, 2026 — Shares of Shivalik Rasayan Ltd closed at ₹385 on September 9, up 20% on the day, continuing a sharp multi-week rally for the Dehradun-based agrochemicals and active pharmaceutical ingredients manufacturer.

The move caps a run that has now included at least three separate double-digit weekly gains in recent months — a pattern that deserves closer examination than the headline percentage alone provides.

Shivalik Rasayan’s current price sits in the middle of an extraordinary swing. The stock hit a 52-week high of ₹496 (with some data providers showing a prior 52-week high closer to ₹651) before collapsing to a 52-week low of ₹206.40 on June 25, 2026 — a decline of roughly 58% from peak to trough. From that low, the stock has now rallied more than 85% in a matter of weeks.

What the Price-Volume Chart Reveals: A Pattern of False Starts

A year-long price-and-volume chart for the stock, spanning October 2025 through this week, adds an important dimension the headline figures alone don’t capture. For most of that year, daily volume sits in a consistently low, quiet band — but it’s punctuated by a small number of sharp, isolated volume spikes that stand well above the surrounding baseline: one in November 2025, a larger one in March 2026, and the single largest spike on the chart prior to this week arriving in June 2026. Each of those earlier spikes coincided with a brief price pop that failed to hold — the stock rose sharply for a session or two, then drifted back down into its prevailing downtrend or sideways range within weeks.

The chart shows the stock grinding down from roughly ₹575-580 in October 2025 to a double-bottom trough in the ₹206-215 zone, revisited twice — once in the spring and again heading into summer 2026 — before a sustained recovery finally took hold beginning in August.

Volume during that August-September climb rose gradually rather than spiking all at once, before culminating this week in the largest single-day volume bar on the entire chart, well above even the June 2026 spike, arriving exactly as price broke out to its highest level since roughly November 2025.

No Single Disclosed Catalyst for Move

Unlike a January 2025 episode when the stock jumped 14.5% specifically on news that its Dahej, Gujarat API facility had received USFDA approval, no comparable company-specific announcement has been identified explaining Wednesday’s 20% move. A review of recent BSE filings shows the most significant recent corporate action is a ₹33 crore capital raise through equity shares and warrants, approved by the board on July 23, 2026, with an Extraordinary General Meeting held August 20, 2026, to secure shareholder approval.

That capital raise — a dilutive event for existing shareholders once warrants are exercised — predates the rally by several weeks and is not, on its own, the kind of announcement that typically drives a same-day price spike of this magnitude.

One disclosure from this same period deserves specific attention. Sanjay Bansal, a former director of Shivalik Rasayan, sold 40,000 equity shares on the open market on June 4, 2026, and then sold a further 60,000 shares between July 24 and July 28, 2026 — worth approximately ₹1.54 crore — according to disclosures tracked by Pocketful.

Valuation Has Run Well Ahead of the Sector

Current metrics show Shivalik Rasayan trading at a meaningfully higher multiple than its industry peers. The stock’s trailing P/E is placed at 43.5x against an average trailing P/E of just 21x for the broader Indian chemicals industry — roughly double the sector norm.

That valuation gap sits awkwardly next to the company’s own longer-term performance. Over the last three years, Shivalik Rasayan’s earnings per share has fallen by an average of 11% per year, while the company’s share price has fallen by 29% per year on average over the same period — meaning the stock has historically underperformed even its own declining earnings trajectory, a pattern the analysis explicitly flagged as the stock “performing significantly worse than earnings.”

Some Genuine Fundamental Improvement, Too

It isn’t all cautionary signals. Simply Wall St’s most recent quarterly data shows real operating improvement: revenue of ₹973 million, up 9% from the prior quarter, and net income of ₹34 million, up 113% quarter-on-quarter, with profit margin improving to 3.5% from 1.8%.

Promoter holding has also remained stable and unchanged at 47.37% through the recent volatility, according to Pocketful, meaning unlike some small-cap red-flag cases, the company’s controlling shareholder group (Growel Remedies Limited) has not been reducing its stake during this period.